Mylan wins FDA approval for generic acid reflux drug
MXLBF | Quote | Chart | News | PowerRating -- Mylan, a US-based generic pharmaceutical company, has reported that its Indian subsidiary, Matrix Laboratories, has received final approval from the FDA for its abbreviated new drug application for lansoprazole delayed-release capsules, 15mg and 30mg.
Lansoprazole delayed-release capsules will be sold under the Mylan Pharmaceuticals brand.
Lansoprazole delayed-release (DR) capsules are the generic version of Tap Pharmaceuticals's proton pump inhibitor Prevacid DR capsules.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on (MXLBF) MXLBF. (MXLBF) has Short Term PowerRatings at TradingMarkets. Details on (MXLBF) Short Term PowerRatings is available at This Link.
- Mylan Inc awarded tentative FDA approval for NDA for Efavirenz Tablets for HIV/AIDS - 12/23/09
- Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets - 12/22/09
- Mylan sells stake in Concord Biotech - 12/14/09
- Matrix Laboratories sells 55% stake in Concord Biotech - 12/09/09
- Mylan Inc awarded FDA approval for generic Prevacid DR Capsules - 11/11/09
- More News >>


